Luteinising hormone-releasing hormone analogues alone in the treatment of advanced disease.

In the treatment of advanced prostate cancer, luteinising hormone-releasing hormone analogue monotherapy is a valuable alternative to standard treatment such as oestrogen therapy or surgical castration. The basis for this is discussed and reference is made to posters presented at the International Symposium on Endocrine Therapy.